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Background: Few studies have assessed long term persisting immunity against hepatitis B virus (HBV) in children
vaccinated during infancy with combined vaccines containing recombinant HBV surface antigen (HBs). We assessed
antibody persistence and immune memory in children 4-5 years of age, previously vaccinated with four doses of
combined hexavalent DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™).
Methods: Immune memory was assessed in 301 children through administration of a challenge dose of
monovalent HBV vaccine.
Results: At 4-5 years of age, 85.3% of subjects had persisting anti-HBs antibody concentrations ≥ 10 mIU/mL, rising
to 98.6% after the HBV challenge dose. All but 12 subjects (95.8%) achieved post-challenge anti-HBs concentrations
≥ 100 mIU/mL. The post-challenge anti-HBs GMC rose by 100-fold compared to pre-challenge concentrations. An
anamnestic response to the HBV vaccine challenge was observed in 96.8% of subjects, including 17/21 (81.0%) of
children with initially undetectable antibodies (<3.3 mIU/mL). All but 4 of 42 subjects (90.5%) with anti-HBs
antibodies <10 mIU/mL prior to the challenge dose, achieved seroprotective levels afterwards. A 4-fold rise in
antibody concentration after the challenge dose was observed in 259/264 (98.1%) of initially seropositive subjects.
The magnitude of the post-challenge responses was proportional to pre-challenge anti-HBs levels. No serious
adverse events were reported during the study.
Conclusion: The combined DTPa-HBV-IPV/Hib vaccine induced lasting immune memory against hepatitis B. Long
term protection afforded by DTPa-HBV-IPV/Hib is likely to be similar to that observed following priming with
monovalent HBV vaccines.
Trial registration: http://www.clinicaltrials.gov 106789 NCT00411697
Background
Achieving high routine vaccination coverage against
hepatitis B in infancy is considered the highest priority
for hepatitis B prevention by the World Health Organi-
zation (WHO) [1]. Universal Infant vaccination as the
primary prevention strategy was adopted by the WHO
in 1988 [2], after the failure of vaccination strategies tar-
geting only at-risk groups [3,4]. Infant vaccination has
the greatest impact on preventing chronic hepatitis B
and its subsequent complications [1]. Furthermore,
maintaining high vaccine coverage is more sustainable
in infants than in adolescents who are difficult to reach
and frequently poorly compliant [3,5-7].
Combination vaccines for use in infancy have an
increasingly important role in contributing to high levels
of parental acceptance of vaccination. Combination vac-
cines reduce the number of injections required for full
vaccination and improve the timeliness of vaccination,
thereby contributing to maintaining high levels of vac-
cine coverage [8,9]. Several combined vaccines * Correspondence: volker.schuster@medizin.uni-leipzig.de
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cially available, the largest of which is the hexavalent
diphtheria-tetanus-pertussis-hepatitis B-inactivated
poliomyelitis and Haemophilus influenzae type b conju-
gate vaccine (DTPa-HBV-IPV/Hib) manufactured by
GlaxoSmithKline Biologicals (GSK, Rixensart, Belgium).
DTPa-HBV-IPV/Hib is licensed for primary vaccina-
tion of infants and for second year of life booster vacci-
nation in many countries throughout the world,
including all European Union countries. Previous clinical
studies have shown DTPa-HBV-IPV/Hib to be well tol-
erated and immunogenic [10]. In particular, three dose
primary vaccination with DTPa-HBV-IPV/Hib induces
seroprotective antibody levels (anti-HBs ≥ 10 mIU/mL)
against hepatitis B in over 95% of subjects [10], compar-
able to results following monovalent hepatitis B vaccines
[10,11]. This study expands upon these previous reports
of DTPa-HBV-IPV/Hib by assessing the persistence of
immunological memory in children between 4 and 5
years of age who had been previously primed and
boosted with four doses of DTPa-HBV-IPV/Hib in their
first two years of life.
Methods
The study was an open-label serological follow up study
(http://www.clinicaltrials.gov 106789 NCT00411697)
conducted in 27 centers in Germany, between 19
December 2006 and 14 May 2007. The study was con-
ducted according to Good Clinical Practice guidelines,
the Declaration of Helsinki, and applicable German
laws. The study protocol was approved by Ethik-Kom-
mission der Landesärztekammer Baden-Württemberg,
Jahnstraße 40, 70597 Stuttgart. Written informed con-
sent was obtained from parents/guardians before
enrolment.
All subjects were healthy and previously vaccinated
with four doses of DTPa-HBV-IPV/Hib (Infanrix hexa™;
GSK Biologicals) administered via routine immunization
procedures in Germany. The recommended infant vacci-
nation schedule in Germany is at 2, 3 and 4 months of
age. Since strict adherence to the schedule could not be
guaranteed, subjects were to have received three primary
vaccination doses by 9 months of age and one booster
dose received between 11 and 18 months of age. Sub-
jects who had received hepatitis B vaccination at birth,
or any previous hepatitis B booster vaccination after
administration of the fourth DTPa-HBV-IPV/Hib dose
in the second year of life were excluded.
Enrolled children received a single challenge dose of
monovalent pediatric hepatitis B vaccine (Engerix™-B
Kinder, containing 10 μg recombinant hepatitis B sur-
face antigen [HBs], GSK) administered intramuscularly
into the deltoid. A blood sample was collected before
and one month after the hepatitis B challenge dose.
Anti-HBs antibodies were measured using GSK Biologi-
cals’ in-house ELISA with a cut-off of 3.3 mIU/mL
defining seropositivity [12]. Anti-HBs antibody concen-
trations ≥ 10 mIU/mL were considered to be
seroprotective.
Serious adverse events occurring within 30 days of
vaccination were recorded.
The primary analysis of immunogenicity was con-
ducted on the according-to-protocol (ATP) immuno-
genicity cohort comprising subjects who complied with
protocol defined procedures and criteria, who received
the challenge hepatitis B vaccine dose, and for whom
immunogenicity data were available.
The percentage of subjects with anti-HBs antibody
concentrations ≥ 10 mIU/mL and ≥ 100 mIU/mL, with
exact 95% confidence intervals (CI), prior to and one
month after the challenge dose, was calculated. Persis-
tence of immunological memory shown by the ability to
mount an anamnestic response to a challenge dose of
hepatitis B vaccine, was defined as anti-HBs concentra-
tions ≥ 10 mIU/mL in subjects seronegative (i.e. anti-
HBs concentrations <3.3 mIU/mL) before the challenge
and as an increase of at least 4-fold in anti-HBs concen-
trations in subjects seropositive (anti-HBs concentra-
tions ≥ 3.3 mIU/mL) before the challenge.
Results
In total, 301 subjects were enrolled and vaccinated. The
ATP immunogenicity cohort consisted of 286 subjects.
Subjects were eliminated from the ATP immunogenicity
analysis because they had received forbidden vaccines;
had not received the full DTPa-HBV-IPV/Hib course in
infancy; had not complied with the blood sampling
schedule; had missing serological data; had blood sam-
ples that could not be reliably identified; or because
they had tested positive to anti-hepatitis B core antigen
(one subject, 0.3%).
The mean age of subjects in the ATP immunogenicity
cohort was 4.5 years (standard deviation [SD] 0.5), of
which 51.7% (148) were female. The majority of subjects
were Caucasian.
Prior to the booster dose, 85.3% (250/293) of DTPa-
HBV-IPV/Hib primed and boosted subjects had persist-
ing anti-HBs levels ≥ 10 mIU/mL. This rose to 98.6%
(282/286) after the HBV challenge dose (Table 1) and
the post-challenge anti-HBs antibody GMC rose by 100-
fold compared to pre-challenge concentrations. All but
12 subjects (95.8%) achieved post-challenge anti-HBs
antibody concentrations ≥ 100 mIU/mL.
An anamnestic response to the hepatitis B vaccine
challenge was observed in 96.8% [95% CI 94.1; 98.5] of
subjects (276/285). Of 21 subjects whose pre-challenge
anti-HBs antibody level was below 3.3 mIU/mL (i.e. ser-
onegative), 17 (81.0%) reached the 10 mIU/mL
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subjects who had anti-HBs antibody concentrations
below 10 mIU/mL prior to the challenge dose, all but 4
(90.5%) achieved seroprotective anti-HBs levels after the
challenge (Table 2). Of 264 subjects with detectable
anti-HBs antibodies prior to the challenge dose, 98.1%
(259) had at least a 4-fold increase in antibody concen-
trations following the challenge dose. The magnitude of
the post-challenge responses was proportional to pre-
challenge anti-HBs levels (Table 2, Figure 1).
No serious adverse events were reported during the
study.
Discussion
Primary and booster vaccination in the first two years of
life with DTPa-HBV-IPV/Hib induced long lived immu-
nological memory against hepatitis B in subjects
between 4 and 5 years of age who had been primed and
boosted via routine pediatric services in Germany.
These data are remarkably similar to data obtained from
cohorts of subjects 4 to 6 years of age primed with
DTPa-HBV-IPV/Hib in clinical trial settings in Ger-
many, where adherence to the primary and booster vac-
cination schedule was likely to have been more strictly
enforced [13,14]. In these studies, anti-HBs antibody
levels associated with seroprotection were observed
between 86.0% and 91% of DTPa-HBV-IPV/Hib trial-
vaccinated subjects at 4-6 years of age [13,14], and an
anamnestic response following HBV vaccine challenge
was observed in 95.7% [14]. A recent follow-up study
conducted in Italy in children in the third year of life,
primed with DTPa-HBV-IPV/Hib at 2, 3 and 11/12
months of age, also showed high persisting seroprotec-
tive anti-HBs levels (96.0% of subjects) and anamnestic
Table 1 Anti-HBs antibody responses before and one month after challenge dose (ATP Cohort for immunogenicity)
Seropositivity/Seroprotection rates
≥ 3.3 mIU/mL ≥ 10 mIU/mL ≥ 100 mIU/mL GMC
Time point N n % [95% CI] n % [95% CI] n % [95% CI] Value [95% CI]
Pre 285 264 92.6 [89.0; 95.4] 243 85.3 [80.6; 89.2] 134 47.0 [41.1; 53.0] 83.7 [66.8; 104.9]
Post 286 284 99.3 [97.5; 99.9] 282 98.6 [96.5; 99.6] 274 95.8 [92.8; 97.8] 8656.1 [6560.7; 11420.9]
GMC = geometric mean antibody concentration. N = number of subjects with available results. n/% = number/percentage of subjects with antibody
concentrations above the specified cut-off. 95% CI = exact 95% confidence interval. Pre = prior to the administration of challenge dose, Post = one month after
the challenge dose
Figure 1 Relationship between anti-HBs antibody concentrations before and after HBV challenge (ATP Immunogenicity cohort).
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with concentrations <10 mIU/mL [15]. Together, these
results provide strong evidence for the immunogenicity
of the hepatitis B component of DTPa-HBV-IPV/Hib in
routine use.
Booster doses of hepatitis B vaccine after primary vac-
cination in immunocompetent individuals are currently
not recommended by either the WHO [16] or the Eur-
opean Consensus group on Hepatitis B Immunity [17].
Decrease of antibody concentrations below seroprotec-
tion level or even below detection levels is not consid-
ered as an indicator of loss of protection. Persisting
protection against clinical hepatitis B disease and
chronic hepatitis B carriage has been shown to last for
up to two decades [17-20].
A potential limitation of the study is that the analysis
was performed, as pre-planned in the protocol, on ATP
immunogenicity cohort. However, fewer than 5% of sub-
jects (15/301) were eliminated from the ATP cohort,
and of these, blood samples were not available or could
not be reliably identified for 5 subjects. It is therefore
unlikely that the conclusions from an analysis of the
Total cohort, with data from only 10 additional subjects,
would differ from the ATP analysis. The findings of the
present study are important because they confirm the
medium term immunogenicity of hepatitis B vaccination
by using a hexavalent combination vaccine in subjects
from a low endemicity region who are unlikely to have
been exposed to hepatitis B, and who were primed with
a large combination vaccine. Further serological follow-
up studies of older individuals until age 15 years, who
received four consecutive doses of DTPa-HBV-IPV/Hib
as primary and booster vaccination in routine vaccina-
tion practice are planned, and will be performed as vac-
cinated cohorts become older.
Conclusions
In conclusion, primary and booster vaccination with
DTPa-HBV-IPV/Hib in infancy induces sustained
seroprotection against hepatitis B up to the age of 4-6
years. A strong response to hepatitis B vaccine challenge
at this age was demonstrated, indicative of persisting
immune memory, even in subjects who had lost circu-
lating antibodies. Longer follow-up is required to ascer-
tain the presence of immune memory at later ages.
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